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Purpose: To assess the efficacy of collagen crosslinking with riboflavin and ultraviolet 
A (UVA) radiation for treatment of early keratoconus.
Methods: Thirty-one eyes of 22 patients with early keratoconus were included in this 
study. All patients underwent slit lamp examination and assessment of uncorrected 
visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), intraocular 
pressure, corneal topography and pachymetry. Collagen crosslinking was performed 
without epithelial removal. Riboflavin was applied to the cornea every 3 minutes 
30 minutes before UVA irradiation and every 5 minutes thereafter. Patients were 
re-assessed 1, 3, and 6 months after treatment.
Results: Postoperatively, UCVA increased by 2 Snellen lines and BSCVA was improved 
by 1.7 Snellen lines (P < 0.001). Spherical equivalent refractive error was reduced 
by 0.55 D, and maximum and mean K values were decreased by 0.65 D and 0.51 D 
respectively (P < 0.05 for all comparisons). Evidence of regression was present in 
71% of treated eyes.
Conclusion: Collagen crosslinking demonstrated significant improvement in vision 
with reduction in corneal power and spherical equivalent refractive error in eyes 
with early keratoconus.
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INTRODuCTION
Keratoconus is a degenerative non-inflammatory 
disease of the cornea, resulting in distortion, 
apical thinning and central scarring. These 
corneal changes lead to decreased vision due to 
high irregular astigmatism and less frequently, 
central corneal scarring. The condition usually 
begins at puberty and tends to progress during 
adolescense.1,2 Treatment consists of glasses, 
rigid contact lenses and intracorneal rings 
early in the disease, however none of these 
modalities affect progression of the condition. 
Eventually, penetrating keratoplasty may be 
required in advanced cases to restore vision.3,4
Collagen crosslinking has been studied 
during recent years by Wollensak and 
colleagues4-9, as well as others10-14. Collagen 
crosslinking, using riboflavin and ultraviolet 
A (UVA) light, has been shown to alter 
the biomechanical, thermomechanical, and 
morphological properties of the cornea. It 
increases corneal rigidity by almost 300% 
and enhances its resistance to proteolytic 
enzymes.7,15-17 Numerous clinical studies on 
collagen crosslinking in progressive keratoconus Collagen Crosslinking for Keratoconus; Derakhshan et al
156 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2011; Vol. 6, No. 3
have shown an arrest in progression and even 
regression in the majority of patients.4,12-14,18,19 
Longitudinal studies have demonstrated visual 
improvement and long-term stable outcomes 
after collagen crosslinking.20 The principal goals 
of such therapy are to increase corneal rigidity, 
stabilize its refractive and biomechanical 
properties and thus improve vision. 
The current study was designed to evaluate 
the effectiveness of this procedure as primary 
treatment for eyes with early keratoconus.
METHODS
This study was performed at Khatam-al-Anbia 
Hospital affiliated to Mashhad University of 
Medical Sciences. Informed written consent was 
obtained from each patient before participation. 
Beginning in January 2008, 31 eyes of 22 patients 
with early keratoconus were enrolled for collagen 
crosslinking. The diagnosis was made based on 
clinical examination and videokeratographic 
findings. Preoperative evaluations included 
measurement of uncorrected visual acuity 
(UCVA), best spectacle-corrected visual acuity 
(BSCVA), intraocular pressure (IOP), corneal 
computerized topography (Technomed, 
Baseweile, Germany), ultrasonic pachymetry 
(Tomey, Erlangen, Germany), and slit lamp 
and fundus examinations. All assessments were 
repeated one, 3, and 6 months after collagen 
crosslinking. Exclusion criteria consisted of 
corneal thickness less than 400 µm, signs of 
advanced keratoconus (Vogt’s striae or corneal 
scarring), history of herpetic keratitis, and 
concurrent infectious or autoimmune disease. 
Since all patients had early keratoconus 
without corneal scarring, we preferred a 
minimally invasive procedure omitting 
epithelial removal which has been shown to 
be equally safe and effective as with epithelial 
removal.14,21 Treatment was performed under 
sterile conditions using topical anesthesia. 
After inserting a wire lid speculum, the 
photosensitizing solution (0.1% riboflavin in 
20% dextran) was instilled every 3 minutes for 
30 minutes. Before UVA exposure, penetration 
of riboflavin into the anterior chamber was 
confirmed by slit lamp examination. A double 
UVA diode was then placed 5 cm from the cornea 
and UVA light irradiated the central cornea at 
370 nm and with radiance of 3 mW/cm2. During 
exposure, the riboflavin solution was applied 
to the cornea every 4 to 5 minutes to ensure 
continuous saturation; balanced salt solution 
was instilled on every 2 minutes to prevent 
dryness and dehydration. After crosslinking, 
a topical antibiotic was prescribed for 5 days.
RESuLTS
Thirty-one eyes of 22 patients including 11 
male and 11 female subjects with mean age of 
22.3 ± 6.8 (range, 15 to 44) years, underwent 
collagen crosslinking for early keratoconus. Mean 
Snellen UCVA was 0.31 ± 0.21 preoperatively 
and 0.51 ± 0.27 postoperatively. Mean Snellen 
BSCVA was 0.72 ± 0.18 preoperatively and 
0.89 ± 0.20 postoperatively (Fig. 1). Comparison 
of preoperative and 6-month follow-up data 
showed an increase of 2.0 ± 1.8 lines in UCVA 
(P < 0.001) and 1.7 ± 1.1 lines in BSCVA 
(P < 0.001). UCVA and BSCVA improved by 
more than one Snellen line in 27 (87%) eyes 
and remained unchanged in four eyes (13%).
Mean spherical equivalent refractive 
error was -5.13 ± 3.67 D preoperatively 
and -4.58 ± 3.27 D postoperatively (Fig. 2). 
Mean reduction in spherical equivalent was 
0.55 ± 0.92 D (P = 0.004) over the follow-up 
period in 22 eyes (71%). 
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Preoperatively, maximum and mean 
keratometric (K) values were 51.21 ± 4.97 D and 
48.38 ± 4.24 D respectively. Postoperatively, 
these values were decreased to 50.56 ± 3.87 D 
and 47.87 ± 3.85 D respectively (Fig. 3). An 
average decrease of 0.65 ± 1.26 D in maximum 
K value (P = 0.007) and 0.51 ± 0.93 D in mean K 
value (P = 0.005) was observed in 24 eyes (77%) 
but the indices remained unchanged in four 
eyes (13%). These results were observed at three 
months and remained stable up to 6 months. 
We observed an increase of 0.12 ± 0.21 D in 
maximum K value (P = 0.17) and 0.10 ± 0.07 D 
in average K value (P = 0.13) in 4 eyes (10%).
In this study, 13 patients were treated 
unilaterally. In 3 of these subjects, the untreated 
fellow eye demonstrated signs of advanced 
keratoconus including one person who had 
previously undergone penetrating keratoplasty; 
4 patients had unilateral keratoconus (the 
fellow eye showed no evidence of ectasia at 
baseline or on subsequent examinations); and 
the remaining 6 individuals showed signs of 
forme frust keratoconus in the contralateral 
eye. In the latter subset of patients four eyes 
(66.6%) demonstrated an average increase of 
0.61 D and 0.46 D in maximum and mean K 
values after 6 months, respectively. 
Mean central corneal thickness (CCT) 
was 485 ± 29.6 µm before treatment and 
494 ± 30.8 µm thereafter; CCT increased by an 
average of 9.1 ± 11.2 µm (P < 0.001).
Mean IOP was 13.5 ± 2.1 mmHg pre- and 
13.6 ± 2.2 mmHg postoperatively (P = 0.565). 
During follow-up, corneal and lenticular 
transparency remained unchanged. Moreover, 
no side effects such as persistent epithelial 
defects or cataracts were encountered.
DISCuSSION
Our study was performed on patients with early 
keratoconus and no signs of advanced disease, 
such as Vogt’s striae and corneal scarring. The 
results showed an increase in vision together 
with a decrease in refractive error and corneal 
curvature.
Vision improved in most patients; this 
improvement began from the first month, slightly 
increased by the third month and remained stable 
up to six months. Visual improvement could 
have been due to the decrease in refractive error, 
corneal steepness and astigmatism. In some cases, 
improvement in UCVA and BSCVA occurred 
before corneal changes were detectable. This 
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Figure 2. Changes in refraction (diopters).
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may have been related to changes in refractive 
index in some areas of the cornea and formation 
of a multifocal cornea.
We observed a statistically significant 
increase in CCT, the clinical significance of 
which remains to be ascertained. Following 
crosslinking, structural corneal changes alter 
the velocity of ultrasound which may influence 
pachymetric findings.20 Another possible 
explanation is that enhanced biomechanical 
rigidity in the cornea may change the pattern 
and distribution of collagen fibers and actually 
increase CCT.7,14 Due to the small number of 
patients and limited follow-up, further studies 
are required to elucidate this matter.
No significant change was observed in 
IOP as measured by Goldmann applanation 
tonometry. We suggest that corneal rigidity 
and its effects on IOP be investigated in future 
studies using the ocular response analyzer 
(ORA).
Topographic findings demonstrated mean 
reduction of 0.65 D in maximum K and 0.51 D 
in average K values in 77% of our patients. 
Wollensak et al4 reported mean reduction 
of 2.01 D in maximum K after 3 years, and 
Caporossi et al13 reported mean reduction of 
2.10 D in maximum K values after 6 months. 
Raiskup-Wolf et al20 described reduced 
curvature of 2.68 D in the first year, 2.21 D in 
the second year, and 4.84 D in the third year. In 
comparison with the above-mentioned studies 
which have been performed in patients with 
progressive keratoconus, our results showed a 
milder effect from crosslinking. This discrepancy 
is probably related to the stage of the disease and 
corneal characteristics such as rigidity, CCT, and 
maximum K values. With gradual progression 
from early to advanced keratoconus, affected 
eyes demonstrate more significant clinical 
findings, decreased biomechanical stiffness, 
and structurally weakened tissue.13,22 Corneal 
rigidity in patients with early keratoconus is 
only slightly less than normal and crosslinking 
possibly induces little change in its structure, 
reflected as a smaller effect from crosslinking. In 
contrast, patients with progressive keratoconus 
have severe corneal changes and very weak 
corneas. Collagen crosslinking in these patients 
probably causes more significant changes in 
refractive error and corneal curvature. We 
believe that the efficacy of collagen crosslinking 
in early and advanced keratoconus may be 
similar; the greater clinical effect seen in 
progressive disease may be due to greater 
reduction in corneal rigidity.
In conclusion, we recommend collagen 
crosslinking for patients with early keratoconus 
who cannot be optically corrected and those 
who demonstrate recent progression. It may be 
preferable to delay such treatment for patients 
that are adequately corrected and show very 
slowly progressive or non-progressive disease. 
Further studies with larger sample size and 
longer follow-up are required to determine the 
optimal time for intervention and the long-term 
effects of crosslinking for early keratoconus.
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